文献速递血液透析通路

药物涂层球囊与传统球囊血管成形术治疗透析通路狭窄的系统综述与荟萃分析

A systematic review and meta-analysis of drug-coated balloon versus conventional balloon angioplasty for dialysis access stenosis.
PubMed 文献 · J Vasc Surg · 2019-01-01

该系统综述与荟萃分析纳入17项研究(8项随机对照试验,9项队列研究),共1113处狭窄透析通路,比较药物涂层球囊(DCB)与传统球囊血管成形术(CBA)的疗效。结果显示DCB组6个月和12个月一期通畅率均显著优于CBA组,且两组轻微并发症发生率均较低。

要点

  • DCB组6个月一期通畅率显著优于CBA组(71.0% vs 49.2%)。
  • DCB组12个月一期通畅率显著优于CBA组(44.2% vs 20.6%)。
  • DCB与CBA的轻微并发症发生率均较低(1.1% vs 0.9%)。

核心结论

  • 对于血液透析通路狭窄患者,DCB血管成形术在6个月和12个月一期通畅率方面优于CBA,且安全性良好。

研究设计与样本

  • 遵循PRISMA指南的系统综述与荟萃分析,检索MEDLINE、Embase和Cochrane Library。
  • 纳入17项研究(8项随机对照试验,9项队列研究),共1113处狭窄透析通路,54.7%接受DCB,45.3%接受CBA。

主要发现

  • 亚组分析显示随机对照试验和队列研究趋势相似,敏感性分析结果一致。
  • DCB组和CBA组轻微并发症合并发生率分别为1.1%和0.9%。

临床怎么用

  • 对于血液透析通路狭窄,尤其是中心静脉狭窄,可考虑使用DCB血管成形术以改善6个月和12个月一期通畅率。
  • 需注意目前证据仍支持开展更大规模试验以确立上述发现。

局限性

  • 研究间存在异质性(6个月I2=62%,12个月I2=53%)。
  • 纳入研究包括队列研究,部分随机对照试验质量较差或采用交叉设计。
  • 作者指出需要更大规模试验来确立这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Arteriovenous fistulas for patients undergoing hemodialysis (HD) are at high risk of stenosis. Despite conventional balloon angioplasty (CBA), restenosis rates are high. The use of a drug-coated balloon (DCB) may offer an alternative to reduce restenosis. METHODS: This study has been performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. An electronic search on MEDLINE, Embase, and the Cochrane Library was performed to identify articles evaluating DCB angioplasty for patients with HD access stenosis. Risk ratios (RRs) of primary patency were pooled, and relevant subgroup and sensitivity analyses were conducted. RESULTS: There were 17 studies (8 randomized controlled trials [RCTs], 9 cohort studies) included, comprising a total of 1113 stenotic dialysis accesses, of which 54.7% underwent DCB angioplasty and 45.3% underwent CBA. There was a significantly superior 6-month (RR, 0.57; 95% confidence interval [CI], 0.44-0.74; P < .00001; I2 = 62%) and 12-month (RR, 0.73; 95% CI, 0.63-0.84; P < .0001; I2 = 53%) primary patency in the DCB angioplasty group in comparison to the CBA group (71.0% vs 49.2% at 6 months; 44.2% vs 20.6% at 12 months). Subgroup analyses of study design (RCTs, cohort studies) showed similar trends. Sensitivity analyses by excluding one poor-quality RCT and those employing the crossover analysis design also showed similar results. Studies investigating central venous stenosis showed significantly better 6-month (RR, 0.57; 95% CI, 0.41-0.79; P = .0009; I2 = 67%) and 12-month (RR, 0.69; 95% CI, 0.56-0.85; P = .0004; I2 = 64%) primary patency in the DCB angioplasty group in comparison to the CBA group. The pooled rate of minor complications was low in both the DCB (1.1%) and CBA (0.9%) groups. CONCLUSIONS: DCB angioplasty appears to be a better and safe alternative to CBA in treating patients with HD stenosis in terms of 6- and 12-month primary patency. However, a larger trial is warranted to establish these findings.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Yan Wee IJ, Yap HY, Hsien Ts'ung LT, et al. A systematic review and meta-analysis of drug-coated balloon versus conventional balloon angioplasty for dialysis access stenosis. J Vasc Surg. 2019. PMID: 31445651. doi:10.1016/j.jvs.2019.01.082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。